• Reichmuth & Co flagged AI capex as a key market driver, with stock performance increasingly tied to revenue gains and margin expansion.
• Recent declines in some AI-linked stocks seen as valuation normalization, not an end to the AI cycle; benefits expected to broaden beyond chipmakers.
• Equity leadership has rotated since mid-May from expensive US tech and semiconductors toward pharmaceuticals and financials, shifting focus to earnings and cash flow.
• Rising long-term US Treasury yields, Middle East escalation risk, August-October seasonality, US midterm elections seen as raising pullback odds.
• Recommended selectivity, disciplined rebalancing, continued AI exposure; favored pharma and biotech for defensiveness, kept conventional energy as a hedge.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Reichmuth & Co published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein.